

ผลของสารสกัดจากขมิ้นชันต่อการแสดงออกของยีนที่เกี่ยวข้องกับการหายใจของแผล
ในเซลล์ไฟโบรบลาสต์จากเหงือกมนุษย์



บทคัดย่อและแฟ้มข้อมูลฉบับเต็มของวิทยานิพนธ์ตั้งแต่ปีการศึกษา 2554 ที่ให้บริการในคลังปัญญาจุฬาฯ (CUIR)
เป็นแฟ้มข้อมูลของนิสิตเจ้าของวิทยานิพนธ์ ที่ส่งผ่านทางบัณฑิตวิทยาลัย

The abstract and full text of theses from the academic year 2011 in Chulalongkorn University Intellectual Repository (CUIR)
are the thesis authors' files submitted through the University Graduate School.

วิทยานิพนธ์นี้เป็นส่วนหนึ่งของการศึกษาตามหลักสูตรปริญญาวิทยาศาสตรมหาบัณฑิต

สาขาวิชาทันตกรรมสำหรับเด็ก ภาควิชาทันตกรรมสำหรับเด็ก

คณะทันตแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย

ปีการศึกษา 2560

ลิขสิทธิ์ของจุฬาลงกรณ์มหาวิทยาลัย

EFFECT OF CURCUMIN ON THE EXPRESSION OF WOUND HEALING-
RELATED GENES IN HUMAN GINGIVAL FIBROBLASTS



A Thesis Submitted in Partial Fulfillment of the Requirements
for the Degree of Master of Science Program in Pediatric Dentistry

Department of Pediatric Dentistry

Faculty of Dentistry

Chulalongkorn University

Academic Year 2017

Copyright of Chulalongkorn University

อัสปรียา รุจิระโชติวัฒน์ : ผลของสารสกัดจากขมิ้นชันต่อการแสดงออกของยีนที่เกี่ยวข้องกับการหายของแผลในเซลล์ไฟโบรบลาสต์จากเหงือกมนุษย์ (EFFECT OF CURCUMIN ON THE EXPRESSION OF WOUND HEALING-RELATED GENES IN HUMAN GINGIVAL FIBROBLASTS) อ.ที่ปรึกษาวิทยานิพนธ์หลัก: อ. ทพญ. ดร.สุภาพร สุทธิมนัสวงษ์, 36 หน้า.

การศึกษาผลของสารสกัดจากขมิ้นชัน (เคอร์คูมิน) ต่อการแสดงออกของยีนที่เกี่ยวข้องกับการหายของแผลในเซลล์ไฟโบรบลาสต์จากเหงือกมนุษย์ซึ่งได้แก่ ยีนทรานสเฟอร์มิงโกรทแฟคเตอร์เบต้าชนิดที่ 1, ยีนทรานสเฟอร์มิงโกรทแฟคเตอร์เบต้ารีเซปเตอร์ชนิดที่ 1, ยีนทรานสเฟอร์มิงโกรทแฟคเตอร์เบต้ารีเซปเตอร์ชนิดที่ 2 และวาสคูลาร์เอนโดทีเลียลโกรทแฟคเตอร์ ความเป็นพิษของเคอร์คูมินถูกทดสอบด้วยวิธีเอ็มทีที จากนั้นทำการกระตุ้นเซลล์ด้วยเคอร์คูมินที่ความเข้มข้นต่างๆเป็นระยะเวลา 24 ชั่วโมงและทำการตรวจสอบการแสดงออกของยีนด้วยวิธีควอนติเททีฟพีซีอาร์ ผลการศึกษาพบว่าเคอร์คูมินที่ความเข้มข้น 0.1-20 ไมโครโมลาร์ไม่มีผลต่อการมีชีวิตของเซลล์ขณะที่ความเข้มข้นที่สูงขึ้น (30 และ 50 ไมโครโมลาร์) มีความเป็นพิษต่อเซลล์ เคอร์คูมินที่ 0.1-20 ไมโครโมลาร์กระตุ้นการแสดงออกของยีนทรานสเฟอร์มิงโกรทแฟคเตอร์เบต้าชนิดที่ 1 ตามความเข้มข้นที่มากขึ้น ในขณะที่ความเข้มข้น 1 ไมโครโมลาร์เป็นความเข้มข้นที่เหมาะสมต่อการกระตุ้นการแสดงออกของยีนทรานสเฟอร์มิงโกรทแฟคเตอร์เบต้ารีเซปเตอร์ชนิดที่ 1, ยีนทรานสเฟอร์มิงโกรทแฟคเตอร์เบต้ารีเซปเตอร์ชนิดที่ 2 และวาสคูลาร์เอนโดทีเลียลโกรทแฟคเตอร์ อย่างไรก็ตามการกระตุ้นแสดงออกของยีนทั้งหมดโดยเคอร์คูมินไม่มีความแตกต่างอย่างมีนัยสำคัญทางสถิติเมื่อเปรียบเทียบกับกลุ่มควบคุม สรุปผลเคอร์คูมินน่าจะมีผลต่อการควบคุมการแสดงออกของยีนที่เกี่ยวข้องกับการหายของแผลในเซลล์ไฟโบรบลาสต์จากเหงือกมนุษย์ แต่จำเป็นต้องมีการศึกษาเพิ่มเติมต่อไป

ภาควิชา ทันตกรรมสำหรับเด็ก

ลายมือชื่อนิสิต

สาขาวิชา ทันตกรรมสำหรับเด็ก

ลายมือชื่อ อ.ที่ปรึกษาหลัก

ปีการศึกษา 2560

5875837532 : MAJOR PEDIATRIC DENTISTRY

KEYWORDS: CURCUMIN, WOUND HEALING, GINGIVAL FIBROBLAST

AUSPREEYA RUJIRACHOTIWAT: EFFECT OF CURCUMIN ON THE EXPRESSION OF WOUND HEALING-RELATED GENES IN HUMAN GINGIVAL FIBROBLASTS.

ADVISOR: SUPAPORN SUTTAMANATWONG, D.D.S., Ph.D., 36 pp.

This study investigated the effect of curcumin on the expression of wound healing-related genes including transforming growth factor beta 1 (TGF- β 1), transforming growth factor beta receptor type I (TGF β R I), transforming growth factor beta receptor type II (TGF β R II) and vascular endothelial growth factor (VEGF) in human gingival fibroblasts. The cytotoxicity of curcumin was determined by MTT assay. Then, cells were treated with non-cytotoxic concentrations of curcumin for 24 hours and the level of gene expression was determined by quantitative polymerase chain reaction (qPCR). Curcumin at 0.1-20 μ M caused no significant change in cell viability while higher concentrations of curcumin (30 and 50 μ M) are cytotoxic. Curcumin dose dependently increased the TGF- β 1 expression while 1 μ M curcumin is the optimal concentration for inducing TGF β R I, TGF β R II, and VEGF expression. However, no statistically significant difference was found in any of these inductions. In conclusion, curcumin may regulate the expression of genes involved in wound healing in human gingival fibroblasts but further investigation is needed.

CHULALONGKORN UNIVERSITY

Department: Pediatric Dentistry

Student's Signature


Field of Study: Pediatric Dentistry

Advisor's Signature

Academic Year: 2017

ACKNOWLEDGEMENTS

First of all, I would like to express my deep gratitude to Dr. Supaporn Suttamanatwong, my thesis advisor, for all the great support and encouragement throughout the course of this thesis. She always gave me valuable suggestions. Moreover, my expression is also extended to thesis committees; Assoc. Prof. Dr. Thipawan Tharapiwattananon, Asst. Prof. Wannakorn Sriarj, and Asst. Prof. Dr. Aroonwan Lam-Ubol for their guidance, kindness and hard questions. This research was supported by the Graduate Research Grant 2018, National Research Council of Thailand. Finally, I would like to thank my family and my friends for their love, understanding and giving me a precious suggestion.



CONTENTS

	Page
THAI ABSTRACT	iv
ENGLISH ABSTRACT	v
ACKNOWLEDGEMENTS	vi
CONTENTS	vii
List of Tables	ix
List of Figures.....	x
Chapter 1 Introduction.....	1
Background and rationale	1
Research question	2
Research Objectives	2
Hypothesis.....	2
Conceptual framework.....	3
Research design.....	3
Keywords	3
Expected Results.....	3
Expected benefits	3
Chapter 2 Review of literature	4
Oral Ulceration and Remedy.....	4
Wound Healing Process	5
Transforming growth factor beta (TGF- β).....	6
Vascular endothelial growth factor (VEGF).....	7
Curcumin.....	8

	Page
Chapter 3 Materials and methods	11
Materials.....	11
Methods.....	12
Cell culture	12
Cell viability assays.....	13
Curcumin treatment.....	13
RNA extraction and Reverse transcription-polymerase chain reaction (RT-PCR)	14
Real-time PCR assay.....	14
Statistical analyses.....	15
Chapter 4 Results	16
Effects of curcumin on the viability of human gingival fibroblasts	16
Effects of curcumin treatment on wound healing-related gene expression.....	17
Chapter 5 Discussion.....	20
REFERENCES	23
APPENDIX.....	32
VITA.....	36

List of Tables

Table 1: Primer sequences used for PCR15



List of Figures

Figure 1 : Four phases of wound healing process	6
Figure 2 : Chemical structures of curcuminoids	8
Figure 3 : Turmeric rhizome	8
Figure 4 : Curcumin cytotoxicity test.....	16
Figure 5 : The expression of TGF- β 1, TGF β R I, TGF β R II and VEGF in human gingival fibroblasts in response to curcumin.	19



Chapter 1

Introduction

Background and rationale

Oral ulceration can cause pain and discomfort which significantly affects daily food intake. Among all of the remedies for oral ulceration, none of them accelerates the healing process [1]. Wound healing is regulated by signals from various cell types including platelets, immune cells, and fibroblasts. Wound healing comprises 4 phases: hemostasis, inflammation, proliferation, and remodeling [2]. In the proliferative phase, gingival fibroblasts work by secreting several growth factors such as transforming growth factor beta (TGF- β) and vascular endothelial growth factor (VEGF) [3]. These biological molecules are crucial for the healing of the wound [4].

Herbal medicine has long been common in eastern cultures despite the western advance medical and pharmaceutical products. Due to the alarm of side effects from the western medicine, the popularity of herbal medicine is even more strengthened and supported by its effectiveness. Curcumin (diferuloylmethane), a yellow substance from turmeric rhizome, is a member of curcuminoid family [5]. In India, curcumin has been widely used for a long time due to its anti-inflammatory, anti-oxidant, anti-bacterial and anti-carcinogenic properties [6].

Curcumin also demonstrates a significant wound healing property by enhancing fibroblast proliferation and increasing the level of antioxidant enzyme in dermal wound of rats [7, 8]. Another study reported that curcumin enhanced collagen production and decreased matrix metalloproteinase-9 production in rat wounds [9]. Curcumin promotes healing of cutaneous wound in both incision and excision models [10]. In

the irradiated wounds, curcumin decreased the healing period by accelerating wound closure and increasing the synthesis of collagen, hexosamine, DNA and nitric oxide [11].

Curcumin has also been reported to promote oral wound healing. An animal study showed that curcumin accelerated the wound healing of mucosal oral ulcer at upper labial gingiva of rabbits [12]. Clinically, topical curcumin gel significantly reduced the size of minor aphthous ulcers in comparison with placebo and pain intensity among these patients [13]. However, the cellular response to curcumin treatment during oral wound healing remains unclear. This study aim to investigate how curcumin affect the expression of genes involved in wound healing in human gingival fibroblasts.

Research question

What is the effect of curcumin on the expression of wound healing-related genes in human gingival fibroblasts?


Research Objectives

1. To examine the effect of curcumin on human gingival fibroblast viability by MTT assay.
2. To determine the effect of curcumin on the expression of TGF- β 1, TGF β R I, TGF β R II, and VEGF in human gingival fibroblasts by qPCR.

Hypothesis

Curcumin can alter the expression of wound healing-related genes in human gingival fibroblasts.

Conceptual framework



Research design

Laboratory experimental research

Keywords

Curcumin, TGF-β1, TGFβR I, TGFβR II, VEGF, gingival fibroblasts

Expected Results

Curcumin can regulate the expression of wound healing-related genes in human gingival fibroblasts.

Expected benefits

This research may provide more understandings of the mechanisms by which curcumin stimulates wound healing. Moreover, curcumin can be further developed as a topical agent to promote oral wound healing.

Chapter 2

Review of literature

Oral Ulceration and Remedy

Oral ulceration is characterized as the complete loss of epithelium with different levels of losing the underlying connective tissue [14]. The common causes are the physical, chemical, thermal or trauma [15-19]. The simplest injuries may develop from daily activities such as accidental biting during mastication or from hard textures of food. Another group of injuries may cause from sharp edges of broken teeth, restorations, and appliances (e.g. orthodontic and prosthodontics appliance) especially ill-fitting dentures, which may cause chronic ulcers. The other group of injuries may be iatrogenic from rotary instrument, saliva ejector, dental material (e.g. sodium hypochlorite) and medicament (e.g. aspirin) during dental treatment. Moreover, one of the most common ulcers is the wound after dental extraction.

Oral ulcers can cause significant pain and discomfort due to the inflammatory process of mucosal lesions as a part of tissue injury response. The inflammation releases a series of inflammatory mediators such as histamine, bradykinins, serotonin, and prostaglandins. These mediators are reported as the factors of pain and hyperalgesia [20-23]. Normally, ulcers can naturally be resolved within a few weeks. However, it takes longer to heal both cutaneous and oral ulcers in patients with systemic conditions such as diabetes mellitus (DM) due to their defective healing process [2, 24]. These patients may benefit from some remedies to relieve the pain and discomfort such as benzydamine hydrochloride mouthwash or spray [1].

Wound Healing Process

The process of wound healing involves four overlapping but distinct phases: hemostasis, inflammation, proliferation, and remodeling [2] (Figure 1). The normal response starts immediately after tissue injury. First, hemostasis is achieved through the platelet aggregation and the formation of blood clots to prevent further blood loss and becoming a provisional matrix for infiltrating cells [25, 26]. In addition to releasing the clotting factors, the platelets also secrete important growth factors such as platelet-derived growth factor (PDGF) and transforming growth factor beta (TGF- β). These mediators trigger the wound healing process by attracting neutrophil, macrophage, endothelial cells, smooth muscle cell and fibroblast into the wound [27]. Second, inflammation is the phase when the neutrophils migrate into the wound area to phagocytose damaged tissues and bacteria [28, 29]. Mast cell release cytokines resulting in inflammation at the wound [30]. Toward the end of the inflammatory phase, the macrophages continue phagocytosis and secrete PDGF and TGF- β to stimulate fibroblast migration and proliferation [2]. Then, fibroblasts migrate into the cleaned area and proliferate. New blood vessels are formed by the process called angiogenesis to restore blood supply to the new tissues [31]. The fibroblasts also synthesize and deposit collagen and new extracellular matrix which result in granulation tissue formation [25]. Re-epithelialization occurs within hours after the injury [26]. The final phase of wound healing involves remodelling of collagen and formation of scar tissue [32].

Although both oral and cutaneous wounds heal through the same 4 phases, they are clinically different [33]. Oral wounds heal more rapidly with less scar formation than cutaneous wounds. The difference in healing could be from the phenotypic

difference between oral and cutaneous fibroblasts [34]. Gingival fibroblasts (GFs) plays important roles in the proliferative phase of oral wound healing [3]. GFs are the connective tissue cell responsible for essential collagen and extracellular matrix deposition for the processes of wound healing and repair [35]. For an effective healing process to occur, various growth factors are required including TGF- β , VEGF, EGF, FGF and Col.




Figure 1 : Four phases of wound healing process

Transforming growth factor beta (TGF- β)

TGF- β plays an important part to control many cellular functions [36]. The 3 isoforms of TGF- β (TGF- β 1, - β 2, - β 3) share 60-80% of the structural similarity but differ in encoded genes. All TGF- β isoforms are secreted as inactive forms that require activation before binding to their specific receptors—receptor type I (TGF β RI) and receptor type II (TGF β RII) [37]. This cytokine is produced by activated macrophages, keratinocytes, platelets, and fibroblasts [38-41]. TGF- β 1 is an important player during healing of the wound by initiating the inflammation, forming the granulation tissue, and stimulating collagen synthesis and wound contraction [42-44]. The expression of TGF- β 1 was remarkably less in non-healing wounds, commonly found in diabetic foot

ulcers and chronic venous leg ulcers compared to normal healing ulcers [45, 46]. Moreover, many studies reported the increasing rate of healing after treating the wounds with exogenous TGF- β 1 [47-49]. Similar to TGF- β 1, TGF- β 2 recruits immune cells and fibroblasts into the wound site leading to angiogenesis, granulation tissue formation and collagen deposition [4]. In contrast, TGF- β 3 has TGF- β 1 antagonistic effect in scar formation. When compared with dermal wounds, the TGF- β 3 to TGF- β 1 ratio is significantly higher in oral wounds, suggesting that TGF- β 3 promotes healing with minimal or no scar formation [50-52]. Furthermore, injection of exogenous TGF- β 3 decreased collagen type I synthesis and scar formation [42, 52].

Vascular endothelial growth factor (VEGF)

The VEGF family includes VEGF-A, VEGF-B, VEGF-C, VEGF-D and placental growth factor (PlGF) [53]. VEGF is produced by endothelial cells, fibroblasts, platelets, neutrophils, and macrophages [54-58]. VEGF binds to the receptor Flt-1 (fms-like tyrosine kinase or VEGFR-1) and KDR (kinase-insert domain containing receptor or VEGFR-2) [59]. VEGF was originally recognized as a vascular permeability factor that helps recruiting inflammatory cells. Up-regulation of VEGF is observed during wound healing [60]. The presence of VEGF is important for inflammation, re-epithelialization, granulation tissue formation, and scar tissue formation during the wound healing. In addition, VEGF stimulates endothelial cells to form new blood vessels. The VEGF-A deficient mice showed the delay of the wound closure because of the reduction of the vessel density [61]. Human and mouse saliva contains high concentrations of VEGF which are primarily secreted from parotid gland and submandibular gland, respectively [62, 63]. Removal of murine submandibular gland resulted in reduction of salivary VEGF level and vessel densities in palatal wound. The decreased salivary VEGF level was correlated with

impaired oral wound healing. Moreover, oral supplement of VEGF in drinking water promoted neovascularization and re-epithelialization in the impaired wounds [64]. Therefore, salivary VEGF is implicated in the superior healing capacity of oral mucosa.

Curcumin

Curcumin (diferuloylmethane) belongs to a family of chemicals known as curcuminoids, a major constituent in turmeric rhizome responsible for its yellow colour [5] (Figure 2 and 3).




Figure 2 : Chemical structures of curcuminoids



Figure 3 : Turmeric rhizome

The accumulating data demonstrated that curcumin is considered as a potent wound healing agent because of its strong anti-oxidant [65], anti-inflammatory [66], and anti-infective activities [67]. Previous studies showed that curcumin promote healing in different types of wounds. Application of curcumin on CO₂ laser-induce skin

wounds promoted re-epithelialization [68]. Previous study also reported faster healing of wounds in the curcumin-treated diabetic mice when compared with the control group. Histological study revealed greater re-epithelialization, migration of numerous cells, neovascularization in the dermis, and deposition of collagen. Moreover, immunohistochemistry showed an increase of TGF- β 1 known to accelerate wound healing suggesting that curcumin might regulate the TGF- β 1 activity [43, 69]. Another study showed that curcumin treatment promoted wound healing possibly by affecting the levels of several enzymes involved in reactive oxygen species production [70]. Furthermore, curcumin significantly protected human keratinocytes and fibroblasts from H₂O₂-induced oxidative damage respectively [71]. Topical application of curcumin to irradiated skin can stimulate wound healing and reduce the expression of cyclooxygenase-2 (COX-2) and nuclear factor-kappa B (NF- κ B) [72]. Curcumin also enhanced blood vessel formation and promoted wound healing by increasing the expression of VEGF and TGF- β 1 in granulation tissues of diabetic rats [73]. For oral wound healing, an animal study demonstrated faster wound healing of mucosal oral ulcer at upper labial gingiva in curcumin-treated group when compared with the control group [12]. Curcumin – ghee formulation and hyaluronic acid is therapeutically effective for periodontal wound healing in dogs. Histologic analysis found substantial decrease in number of the inflammatory cells and acceleration of wound healing process [74]. Clinical study showed that turmeric gel can be a good adjunctive treatment to routine periodontal prophylaxis and deep cleaning [75]. The authors reported significant improvement of all clinical periodontal parameters in comparison with control group [75]. Moreover, curcumin gel has been shown to significantly reduce the severity and the size of lesion of mucositis in patients undergoing head and neck

cancer radiotherapy [76, 77]. Similarly, curcumin mouthwash expedited wound healing compared with 0.2% chlorhexidine mouthwash in radio-chemotherapy-induced oral mucositis patients [78]. These data has established the benefits of curcumin in acceleration of wound healing.



Chapter 3

Materials and methods

Materials

1. Dulbecco's modified Eagle's medium (DMEM); Sigma, USA
2. Fetal bovine serum (FBS); Gibco, USA
3. L-glutamine; Gibco, USA
4. Antibiotic-antimycotic solution; Gibco, USA
5. Phosphate buffered saline (PBS); Gibco, USA
6. 0.25% Trypsin-EDTA; Gibco, USA
7. 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT);

Invitrogen, USA

8. Curcumin; Sigma, USA
9. Primers for TGF- β 1; Wardmedic, Thailand
10. Primers for TGF β R I; Wardmedic, Thailand
11. Primers for TGF β R II; Wardmedic, Thailand
12. Primers for VEGF; Wardmedic, Thailand
13. Total RNA MiNi kit; Geneaid, USA
14. DNase I, RNase-free; Thermo scientific, USA
15. Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV RT);

Promega, USA

16. dNTP Mix, Thermo scientific, USA
17. Ribolock RNase inhibitor, Thermo scientific, USA
18. Tag DNA polymerase; Thermo scientific, USA
19. iTaqTM Universal SYBR[®] Green Supermix; Bio-Rad, USA

20. ELISA kit; R&D Systems, USA
21. Nuclease free water
22. Dimethylsulfoxide (DMSO)
23. Distilled water
24. Agarose
25. Ethidium bromide
26. Absolute ethanol
27. 70% ethanol
28. Microcentrifuge tubes
29. PCR tubes
30. Disposable pipette tips (10, 200, and 1000 microlitre)
31. 60- and 100-mm tissue culture dishes
32. 24- and 96-wells tissue culture polystyrene plates
33. Disposable latex gloves

Methods

Cell culture

Human gingival fibroblasts were prepared from healthy gingival tissue explants from patients who were undergoing a minor oral surgery such as tooth extraction or surgical removal of third molars for orthodontic reasons. The complete consent forms were obtained from the subjects. The study protocol was approved by the Ethics Committee of the Faculty of Dentistry, Chulalongkorn University.

The gingival tissue was removed from the cervical third of extracted tooth with scalpel, and then washed twice with PBS. The collected gingival tissue was cut into small pieces and placed in tissue culture dishes (60-mm dishes) with the DMEM

supplement consisting of 10% FBS, 1% L-glutamine, and 1% Antibiotic-Antimycotic, under the humidified atmosphere with 37°C and 5% carbon dioxide. Once confluent, the cells were subcultured with 0.125% trypsin. During the subculturing, the medium was renewed every 2 days. The cells from the third to the fifth passage were used in the experiments.

Cell viability assays

To determine curcumin toxicity, human gingival fibroblasts were plated at 5×10^3 cells per well in 96-well flat-bottomed tissue culture plates in DMEM with 10% FBS for 24 hours. Next, the medium was changed to the serum-free-DMEM containing 0-50 μM of curcumin and then incubated for another 24 hours. Following incubation, cell viability was measured by the MTT assay. After removing the culture media, 100 μL of the MTT solution was added into each well and incubated for 90 minutes until the formazan crystal formation was visible under the microscope. At the end of the incubation period, the MTT solution was removed, and 100 μL of DMSO was added to the well and swirled gently to solubilize the formed formazan crystals. Absorbance of the dye was measured using a plate reader (EZ Read 400; Biochrom) at a wavelength of 570 nm. Cell survival was calculated as follows:

$$\text{Percentage of survival} = (\text{mean experimental absorbance}/\text{mean control absorbance}) \times 100$$

Curcumin treatment

To study the effect of curcumin on gene expression, human gingival fibroblasts were plated at 6×10^5 cells per plate in tissue culture dishes (60-mm dishes) in DMEM with 10% FBS. On the following day, the cells were washed and switched to serum-

free DMEM for 24 hours. After that, the cells were treated with 0, 0.1, 1, 10, 20 μM of curcumin for 24 hours.

RNA extraction and Reverse transcription-polymerase chain reaction (RT-PCR)

Total RNA was extracted using the Total RNA Mini Kit. The concentration of the RNA is was determined by measuring the absorbance at 260 and 280 nm with a Thermo Scientific NanoDrop™ 2000 Spectrophotometer. Total RNA (2 μg) was reverse transcribed by Moloney Murine Leukemia Virus Reverse Transcriptase according to the manufacturer's instruction.

Real-time PCR assay

The cDNA template was amplified by iTaq™ Universal SYBR® Green Supermix. The mixture contains 5 μL of using iTaq™ Universal SYBR® Green Supermix (2x), 0.25 μL of each primer, 2.5 μL of DNA template. Nuclease-free water was added to a final volume of 10 μL . The PCR program setting was at 95°C for 5 min followed by 45 cycles for the amplification phase; each consists of denaturation for 30 sec at 95°C, annealing for 30 sec at 56°C for GAPDH and 50°C for other genes, and extension for 30 sec at 72°C. The sequences of PCR primers are shown in Table 1.

Table 1: Primer sequences used for PCR

Gene	Primer sequences	Product size
TGF- β 1	Forward: 5'-GGATACCAACTATTGCTTCAGCTCC-3' Reverse: 5'-AGGCTCCAAATGTAGGGGCAGGGCC-3'	156
TGF β R I	Forward: 5'-GGTCTTGCCCATCTTCACAT-3' Reverse: 5'-TCTGTGGCTGAATCATGTCT-3'	155
TGF β R II	Forward: 5'-GTCTACTCCATGGCTCTGGT-3' Reverse: 5'-ATCTGGATGCCCTGGTGGTT-3'	197
VEGF	Forward: 5'-AGACCCTGGTGGACATCTTC-3' Reverse: 5'-TGCATTACATTTGTTGT GC-3'	225
GAPDH	Forward: 5'-TGAACGGGAAGCTCACTGG-3' Reverse: 5'-TCCACCACCCTGTTGCTGTA-3'	307

Statistical analyses

Each experiment was repeated at least 3 times using gingival fibroblasts from 3 different subjects. The data were reported as mean \pm standard deviation (SD). Statistical analyses were performed using one-way ANOVA test followed by post-hoc or Kruskal-Wallis test followed by Mann-Whitney U test. The differences at $p < 0.05$ was considered as statistically significant.

Chapter 4

Results

Effects of curcumin on the viability of human gingival fibroblasts

Our results demonstrated that curcumin at 0.1-20 μM caused no significant change in cell viability, whereas 30 and 50 μM curcumin caused a significant cytotoxicity ($p < 0.05$) (Figure 4). Therefore, curcumin at 0.1-20 μM was used in the subsequent experiments.







Figure 4 : Cytotoxicity test. Human gingival fibroblasts were plated at 5×10^3 cells per well in 96-well plates, then treated with varying concentrations of curcumin or DMSO for 24 hours. The cell viability was measured by MTT assay. The data showed percentage of cell viability compared to untreated group at 24 hours. *indicates compared to the untreated group; $p < 0.05$.

Effects of curcumin treatment on wound healing-related gene expression

The expression of TGF- β 1, TGF β R I, TGF β R II and VEGF was determined after treating human gingival fibroblasts with various curcumin concentrations (0-20 μ M) for 24 hours. The data showed that curcumin at the concentrations of 0.1-20 μ M slightly increased TGF- β 1 expression in a dose-dependent manner. On the other hand, only curcumin at 1 and 10 μ M mostly increased TGF β R I, TGF β R II and VEGF expression. However, none of these induction showed statistical significant difference from untreated group (Figure 5).








Figure 5 : The expression of TGF- β 1 (A), TGF β R I (B), TGF β R II (C) and VEGF (D) in human gingival fibroblasts in response to curcumin. Cells were plated at 6×10^5 cells per plate in tissue culture dishes, then treated with varying concentrations of curcumin or DMSO for 24 hours. The level of genes expression was determined with the real-time PCR. The data are the mean \pm SD. Kruskal-Wallis H analysis showed no statistical significance.

Chapter 5

Discussion

Previous studies demonstrated that curcumin enhanced wound healing in several animal models [9, 11, 12]. However, the mechanism by which curcumin promotes healing of wounds remains unclear. This study investigated the effect of curcumin on the wound healing-related gene expression in human gingival fibroblasts. First, we determined the non-cytotoxic concentration of curcumin on human gingival fibroblasts. We found that curcumin at 0.1 - 20 μM did not significantly affect cell viability while 30 and 50 μM is cytotoxic. Chen et al. reported a similar finding that curcumin at 1-10 μM is not toxic to human gingival fibroblasts [79]. However, curcumin cytotoxicity was demonstrated at the concentration of 20 μM for renal fibroblasts [80]. These data suggest that the non-cytotoxic concentration of curcumin is different for each cell types and must be taken into consideration for the clinical application.

There are many growth factors that are secreted in response to injury and during wound healing. TGF- β signaling plays an important role for wound healing including scar formation and tissue regeneration [81]. TGF- β signals through TGF β R I/II that stimulate small mothers against decapentaplegic (Smad) protein in the cytoplasm to regulate the transcription of target genes [81]. Previous study showed that topical application of exogenous TGF- β 1 expedited the rate of wound healing [47-49]. Mani et al. reported an increased expression of TGF- β 1, mainly in macrophages, and TGF β R II in curcumin treated wounds, at both the protein and mRNA level [41]. Curcumin also increased TGF β R I expression in dexamethasone-impaired wounds [41]. Moreover, curcumin promoted the healing of indomethacin-induced gastric ulceration by enhancing collagenization and angiogenesis via induction of matrix metalloproteinase

(MMP)-2, TGF- β and VEGF at protein and mRNA levels [82]. Another study demonstrated that topical application of curcumin ointment promoted cutaneous wound healing in excisional model in rats by increasing the level of TGF- β 1 as compare with control [83]. Sidhu et al. reported faster closure of curcumin-treated wound characterized by enhanced granular tissue formation through the increased expression of TGF- β in both normal and diabetic mice [69, 84].

VEGF is responsible for stimulating angiogenesis during wound healing [85]. VEGF acts predominantly through two high-affinity receptor tyrosine kinases including VEGFR-1 and VEGFR-2 [59]. Wilgus et al. demonstrated the importance of VEGF signaling by treating the wounds with anti-VEGFR-1 or inhibitors of VEGF signaling which resulted in delayed wound healing [86]. Sharma et al. showed that curcumin hastened the healing of indomethacin-induced ulcer by angiogenesis and collagenization via accelerating the expression of VEGF and TGF- β 1 at earlier time points in wound healing process [82]. Furthermore, curcumin promoted neovascularization and accelerated wound healing in diabetic rats by increasing VEGF and TGF- β 1 mRNA expressions [73].

Our results showed no significant difference in TGF- β 1, TGF β R I, TGF β R II and VEGF gene expression between curcumin treatment and control group. This probably due to some limitation of this *in vitro* model. It is well known that wound healing process requires various growth factors or various signal interactions from several cell types. Topman et al. showed that curcumin had no effect on fibroblast migration in the scratch test[31]. These results suggested that fibroblast migration is dependent on different factors which is not possible to mimic in an *in vitro* assay [31]. Mani et al. found that curcumin increases TGF- β 1 expression in the wound, mainly in macrophages [41]. Therefore, fibroblasts may not be the main target cell of curcumin. Previous study

demonstrated that curcumin stimulated expression and secretion of interleukin-1 (IL-1) in macrophage [87]. Another study reported that IL-1 which mainly produced by macrophage induced VEGF expression in synovial fibroblasts [88]. Curcumin increased transcription and secretion of anti-inflammatory factors such as TGF- β in activated macrophage which stimulated collagen type I synthesis in fibroblasts [89, 90]. Therefore, curcumin may have an indirect effect on fibroblasts by acting on other cell types such as macrophages or lymphocytes which in turn regulate gene expression in fibroblasts [91]. Furthermore, normal fibroblasts and wounded fibroblasts are phenotypically different [92]. Wounded fibroblasts undergo several phenotypical changes including decreased proliferation potential, increased collagen synthesis and matrix contraction [93, 94]. Moreover, wounded fibroblasts spontaneously synthesize nitric oxide while normal fibroblasts required stimulation [92]. Therefore, an *in vitro* wound healing model that simulating the wound in human gingival fibroblast culture is another way to study the effect of curcumin on wound healing.

In summary, our results showed that curcumin did not significantly alter the mRNA expression of TGF- β 1, TGF β R I, TGF β R II and VEGF in human gingival fibroblasts at 24 hours after treatment. However, further studies are required to investigate the mechanism of curcumin to promote wound healing.

REFERENCES

1. Scully, C. and R. Shotts, *Mouth ulcers and other causes of orofacial soreness and pain*. The Western journal of medicine, 2001. **174**(6): p. 421.
2. Diegelmann, R.F. and M.C. Evans, *Wound healing: an overview of acute, fibrotic and delayed healing*. Front Biosci, 2004. **9**: p. 283-9.
3. Aukhil, I., *Biology of wound healing*. Periodontology 2000, 2000. **22**(1): p. 44-50.
4. Barrientos, S., et al., *Growth factors and cytokines in wound healing*. Wound Repair Regen, 2008. **16**(5): p. 585-601.
5. Sharma, et al., *Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance*. Clin Cancer Res, 2004. **10**(20): p. 6847-54.
6. Chattopadhyay, I., et al., *Turmeric and curcumin: Biological actions and medicinal applications*. CURRENT SCIENCE-BANGALORE-, 2004. **87**: p. 44-53.
7. Akbik, D., et al., *Curcumin as a wound healing agent*. Life Sci, 2014. **116**(1): p. 1-7.
8. Gopinath, D., et al., *Dermal wound healing processes with curcumin incorporated collagen films*. Biomaterials, 2004. **25**(10): p. 1911-7.
9. Bhagavathula, N., et al., *A combination of curcumin and ginger extract improves abrasion wound healing in corticosteroid-impaired hairless rat skin*. Wound Repair Regen, 2009. **17**(3): p. 360-6.
10. Gong, C., et al., *A biodegradable hydrogel system containing curcumin encapsulated in micelles for cutaneous wound healing*. Biomaterials, 2013. **34**(27): p. 6377-87.
11. Jagetia, G.C. and G.K. Rajanikant, *Role of curcumin, a naturally occurring phenolic compound of turmeric in accelerating the repair of excision wound, in mice whole-body exposed to various doses of gamma-radiation*. J Surg Res, 2004. **120**(1): p. 127-38.
12. Lim, Y.S., et al., *Enhanced mucosal healing with curcumin in animal oral ulcer model*. Laryngoscope, 2016. **126**(2): p. E68-73.

13. Manifar, S., et al., *Curcumin gel in the treatment of minor aphthous ulcer: A randomized, placebo-controlled trial*. Journal of Medicinal Plants, 2012. **1**(41): p. 40-45.
14. Scully, C. and S. Porter, *Orofacial disease: update for the dental clinical team: 2. Ulcers, erosions and other causes of sore mouth. Part I*. Dent Update, 1998. **25**(10): p. 478-84.
15. Anura, A., *Traumatic oral mucosal lesions: a mini review and clinical update*. Oral Health Dent Manag, 2014. **13**(2): p. 254-9.
16. Baricevic, M., et al., *Oral mucosal lesions during orthodontic treatment*. Int J Paediatr Dent, 2011. **21**(2): p. 96-102.
17. Maron, F.S., *Mucosal burn resulting from chewable aspirin: report of case*. J Am Dent Assoc, 1989. **119**(2): p. 279-80.
18. Hulsmann, M. and W. Hahn, *Complications during root canal irrigation--literature review and case reports*. Int Endod J, 2000. **33**(3): p. 186-93.
19. Van Heerden, W.F. and S.C. Boy, *Diagnosis and management of common non-viral oral ulcerations*. South African Family Practice, 2007. **49**(8): p. 20-26.
20. Dray, A., *Inflammatory mediators of pain*. Br J Anaesth, 1995. **75**(2): p. 125-31.
21. Dray, A. and M. Perkins, *Bradykinin and inflammatory pain*. Trends Neurosci, 1993. **16**(3): p. 99-104.
22. Funk, C.D., *Prostaglandins and leukotrienes: advances in eicosanoid biology*. Science, 2001. **294**(5548): p. 1871-5.
23. Sommer, C., *Serotonin in pain and analgesia: actions in the periphery*. Mol Neurobiol, 2004. **30**(2): p. 117-25.
24. Diabetes, C., et al., *Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005)*. Arch Intern Med, 2009. **169**(14): p. 1307-16.
25. Enoch, S., J.E. Grey, and K.G. Harding, *Recent advances and emerging treatments*. BMJ: British Medical Journal, 2006. **332**(7547): p. 962.

26. Singer, A.J. and R.A. Clark, *Cutaneous wound healing*. New England journal of medicine, 1999. **341**(10): p. 738-746.
27. Kim, W.J.-H., G.K. Gittes, and M.T. Longaker, *Signal transduction in wound pharmacology*. Archives of pharmacal research, 1998. **21**(5): p. 487-495.
28. Hart, J., *Inflammation. 1: Its role in the healing of acute wounds*. J Wound Care, 2002. **11**(6): p. 205-9.
29. Sylvia, C.J., *The role of neutrophil apoptosis in influencing tissue repair*. J Wound Care, 2003. **12**(1): p. 13-6.
30. Artuc, M., et al., *Mast cells and their mediators in cutaneous wound healing--active participants or innocent bystanders?* Exp Dermatol, 1999. **8**(1): p. 1-16.
31. Topman, G., F.H. Lin, and A. Gefen, *The natural medications for wound healing - Curcumin, Aloe-Vera and Ginger - do not induce a significant effect on the migration kinematics of cultured fibroblasts*. J Biomech, 2013. **46**(1): p. 170-4.
32. Eckes, B., et al., *Fibroblast-matrix interactions in wound healing and fibrosis*. Matrix Biol, 2000. **19**(4): p. 325-32.
33. Sciubba, J.J., J.P. Waterhouse, and J. Meyer, *A fine structural comparison of the healing of incisional wounds of mucosa and skin*. Journal of Oral Pathology & Medicine, 1978. **7**(4): p. 214-227.
34. Shannon, D.B., et al., *Phenotypic differences between oral and skin fibroblasts in wound contraction and growth factor expression*. Wound Repair Regen, 2006. **14**(2): p. 172-8.
35. Chiquet, M., C. Katsaros, and D. Kletsas, *Multiple functions of gingival and mucoperiosteal fibroblasts in oral wound healing and repair*. Periodontol 2000, 2015. **68**(1): p. 21-40.
36. Tirado-Rodriguez, B. and E. Ortega, *TGF- beta: an important mediator of allergic disease and a molecule with dual activity in cancer development*. 2014. **2014**: p. 318481.
37. Klass, B.R., A.O. Grobbelaar, and K.J. Rolfe, *Transforming growth factor beta1 signalling, wound healing and repair: a multifunctional cytokine with clinical implications for wound repair, a delicate balance*. Postgrad Med J, 2009. **85**(999): p. 9-14.

38. Lee, H.S., et al., *Modulation of TGF-beta 1 production from human keratinocytes by UVB*. *Exp Dermatol*, 1997. **6**(2): p. 105-10.
39. Eppley, B.L., J.E. Woodell, and J. Higgins, *Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing*. *Plast Reconstr Surg*, 2004. **114**(6): p. 1502-8.
40. Wu, L., et al., *Macrophage colony-stimulating factor accelerates wound healing and upregulates TGF-beta1 mRNA levels through tissue macrophages*. *J Surg Res*, 1997. **72**(2): p. 162-9.
41. Mani, H., et al., *Curcumin differentially regulates TGF-beta1, its receptors and nitric oxide synthase during impaired wound healing*. *Biofactors*, 2002. **16**(1-2): p. 29-43.
42. Pakyari, M., et al., *Critical Role of Transforming Growth Factor Beta in Different Phases of Wound Healing*. *Adv Wound Care (New Rochelle)*, 2013. **2**(5): p. 215-224.
43. Montesano, R. and L. Orci, *Transforming growth factor beta stimulates collagen-matrix contraction by fibroblasts: implications for wound healing*. *Proc Natl Acad Sci U S A*, 1988. **85**(13): p. 4894-7.
44. Desmouliere, A., et al., *Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts*. *J Cell Biol*, 1993. **122**(1): p. 103-11.
45. Cowin, A.J., et al., *Effect of healing on the expression of transforming growth factor beta(s) and their receptors in chronic venous leg ulcers*. *J Invest Dermatol*, 2001. **117**(5): p. 1282-9.
46. Jude, E.B., et al., *Transforming growth factor-beta 1, 2, 3 and receptor type I and II in diabetic foot ulcers*. *Diabet Med*, 2002. **19**(6): p. 440-7.
47. Quaglino, D., Jr., et al., *Transforming growth factor-beta stimulates wound healing and modulates extracellular matrix gene expression in pig skin: incisional wound model*. *J Invest Dermatol*, 1991. **97**(1): p. 34-42.
48. Quaglino, D., Jr., et al., *Transforming growth factor-beta stimulates wound healing and modulates extracellular matrix gene expression in pig skin. I. Excisional wound model*. *Lab Invest*, 1990. **63**(3): p. 307-19.

49. Mustoe, T.A., et al., *Accelerated healing of incisional wounds in rats induced by transforming growth factor-beta*. *Science*, 1987. **237**(4820): p. 1333-6.
50. Waddington, S.N., et al., *Gene delivery of a mutant TGFbeta3 reduces markers of scar tissue formation after cutaneous wounding*. *Mol Ther*, 2010. **18**(12): p. 2104-11.
51. Schrementi, M.E., et al., *Site-specific production of TGF-beta in oral mucosal and cutaneous wounds*. *Wound Repair Regen*, 2008. **16**(1): p. 80-6.
52. Hosokawa, R., et al., *TGF-beta 3 decreases type I collagen and scarring after labioplasty*. *J Dent Res*, 2003. **82**(7): p. 558-64.
53. Saaristo, A., et al., *Vascular endothelial growth factor-C accelerates diabetic wound healing*. *Am J Pathol*, 2006. **169**(3): p. 1080-7.
54. Namiki, A., et al., *Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells*. *J Biol Chem*, 1995. **270**(52): p. 31189-95.
55. Detsch, R., et al., *Increase in VEGF secretion from human fibroblast cells by bioactive glass S53P4 to stimulate angiogenesis in bone*. *J Biomed Mater Res A*, 2014. **102**(11): p. 4055-61.
56. Banks, R.E., et al., *Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology*. *Br J Cancer*, 1998. **77**(6): p. 956-64.
57. Gaudry, M., et al., *Intracellular pool of vascular endothelial growth factor in human neutrophils*. *Blood*, 1997. **90**(10): p. 4153-61.
58. Berse, B., et al., *Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors*. *Mol Biol Cell*, 1992. **3**(2): p. 211-20.
59. Thomas, K.A., *Vascular endothelial growth factor, a potent and selective angiogenic agent*. *J Biol Chem*, 1996. **271**(2): p. 603-6.
60. Brown, L.F., et al., *Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing*. *J Exp Med*, 1992. **176**(5): p. 1375-9.

61. Rossiter, H., et al., *Loss of vascular endothelial growth factor activity in murine epidermal keratinocytes delays wound healing and inhibits tumor formation*. *Cancer Res*, 2004. **64**(10): p. 3508-16.
62. Mandel, I.D., *The functions of saliva*. *Journal of dental research*, 1987. **66**(2 suppl): p. 623-627.
63. Taichman, N.S., et al., *Vascular endothelial growth factor in normal human salivary glands and saliva: a possible role in the maintenance of mucosal homeostasis*. *Lab Invest*, 1998. **78**(7): p. 869-75.
64. Keswani, S.G., et al., *Role of salivary vascular endothelial growth factor (VEGF) in palatal mucosal wound healing*. *Wound Repair Regen*, 2013. **21**(4): p. 554-62.
65. Meng, B., J. Li, and H. Cao, *Antioxidant and antiinflammatory activities of curcumin on diabetes mellitus and its complications*. *Curr Pharm Des*, 2013. **19**(11): p. 2101-13.
66. Liang, G., et al., *Synthesis, crystal structure and anti-inflammatory properties of curcumin analogues*. *Eur J Med Chem*, 2009. **44**(2): p. 915-9.
67. Mun, S.H., et al., *Synergistic antibacterial effect of curcumin against methicillin-resistant Staphylococcus aureus*. *Phytomedicine*, 2013. **20**(8-9): p. 714-8.
68. Lopez-Jornet, P., et al., *Topical curcumin for the healing of carbon dioxide laser skin wounds in mice*. *Photomed Laser Surg*, 2011. **29**(12): p. 809-14.
69. Sidhu, G.S., et al., *Curcumin enhances wound healing in streptozotocin induced diabetic rats and genetically diabetic mice*. *Wound Repair Regen*, 1999. **7**(5): p. 362-74.
70. Panchatcharam, M., et al., *Curcumin improves wound healing by modulating collagen and decreasing reactive oxygen species*. *Mol Cell Biochem*, 2006. **290**(1-2): p. 87-96.
71. Phan, T.T., et al., *Protective effects of curcumin against oxidative damage on skin cells in vitro: its implication for wound healing*. *J Trauma*, 2001. **51**(5): p. 927-31.

72. Kim, J., et al., *Therapeutic effect of topical application of curcumin during treatment of radiation burns in a mini-pig model*. J Vet Sci, 2016. **17**(4): p. 435-444.
73. Kant, V., et al., *Curcumin-induced angiogenesis hastens wound healing in diabetic rats*. J Surg Res, 2015. **193**(2): p. 978-88.
74. Habiboallah, G., et al., *Histological evaluation of Curcuma longa-ghee formulation and hyaluronic acid on gingival healing in dog*. J Ethnopharmacol, 2008. **120**(3): p. 335-41.
75. Behal, R., et al., *Evaluation of local drug-delivery system containing 2% whole turmeric gel used as an adjunct to scaling and root planing in chronic periodontitis: A clinical and microbiological study*. J Indian Soc Periodontol, 2011. **15**(1): p. 35-8.
76. Mansourian, A., et al., *The effect of "Curcuma Longa" topical gel on radiation-induced oral mucositis in patients with head and neck cancer*. INTERNATIONAL JOURNAL OF RADIATION RESEARCH, 2015. **13**(3): p. 269-274.
77. Francis, M. and S. Williams, *Effectiveness of Indian Turmeric Powder with Honey as Complementary Therapy on Oral Mucositis: A Nursing Perspective among Cancer Patients in Mysore*. The Nursing journal of India, 2013. **105**(6): p. 258-260.
78. Patil, K., et al., *Use of Curcumin Mouthrinse in Radio-Chemotherapy Induced Oral Mucositis Patients: A Pilot Study*. J Clin Diagn Res, 2015. **9**(8): p. Zc59-62.
79. Chen, J.T., C.Y. Wang, and M.H. Chen, *Curcumin inhibits TGF-beta1-induced connective tissue growth factor expression through the interruption of Smad2 signaling in human gingival fibroblasts*. J Formos Med Assoc, 2018.
80. Gaedeke, J., N.A. Noble, and W.A. Border, *Curcumin blocks multiple sites of the TGF-beta signaling cascade in renal cells*. Kidney Int, 2004. **66**(1): p. 112-20.
81. Gilbert, R.W., M.K. Vickaryous, and A.M. Vilorio-Petit, *Signalling by transforming growth factor beta isoforms in wound healing and tissue regeneration*. Journal of Developmental Biology, 2016. **4**(2): p. 21.

82. Sharma, et al., *Curcumin heals indomethacin-induced gastric ulceration by stimulation of angiogenesis and restitution of collagen fibers via VEGF and MMP-2 mediated signaling*. *Antioxid Redox Signal*, 2012. **16**(4): p. 351-62.
83. Prasad, R., et al., *Curcumin Enhanced Cutaneous Wound Healing by Modulating Cytokines and Transforming Growth Factor in Excision Wound Model in Rats*. *Int. J. Curr. Microbiol. App. Sci*, 2017. **6**(7): p. 2263-2273.
84. Sidhu, G.S., et al., *Enhancement of wound healing by curcumin in animals*. *Wound Repair Regen*, 1998. **6**(2): p. 167-77.
85. Leung, D.W., et al., *Vascular endothelial growth factor is a secreted angiogenic mitogen*. *Science*, 1989. **246**(4935): p. 1306-9.
86. Wilgus, T.A., et al., *Novel function for vascular endothelial growth factor receptor-1 on epidermal keratinocytes*. *Am J Pathol*, 2005. **167**(5): p. 1257-66.
87. Larmonier, C.B., et al., *Modulation of neutrophil motility by curcumin: implications for inflammatory bowel disease*. *Inflamm Bowel Dis*, 2011. **17**(2): p. 503-15.
88. Ben-Av, P., et al., *Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis*. *FEBS Lett*, 1995. **372**(1): p. 83-7.
89. Pierce, G.F., et al., *Transforming growth factor beta reverses the glucocorticoid-induced wound-healing deficit in rats: possible regulation in macrophages by platelet-derived growth factor*. *Proc Natl Acad Sci U S A*, 1989. **86**(7): p. 2229-33.
90. Wang, J., et al., *Enhancement of Anti-Inflammatory Activity of Curcumin Using Phosphatidylserine-Containing Nanoparticles in Cultured Macrophages*. *Int J Mol Sci*, 2016. **17**(5).
91. Barbul, A., *Immune aspects of wound repair*. *Clin Plast Surg*, 1990. **17**(3): p. 433-42.
92. Schaffer, M.R., et al., *Nitric oxide, an autocrine regulator of wound fibroblast synthetic function*. *J Immunol*, 1997. **158**(5): p. 2375-81.
93. Regan, M.C., et al., *The wound environment as a regulator of fibroblast phenotype*. *J Surg Res*, 1991. **50**(5): p. 442-8.

94. Germain, L., et al., *Human wound healing fibroblasts have greater contractile properties than dermal fibroblasts*. *J Surg Res*, 1994. **57**(2): p. 268-73.



APPENDIX

Statistical analysis

Test of normality (% cell viability)

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
%viability	.030	336	.200 [*]	.992	336	.080

a. Lilliefors Significance Correction

*. This is a lower bound of the true significance.



Statistical analysis of % cell viability by one-way ANOVA test

ANOVA

%viability

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	37944.614	6	6324.102	22.703	.000
Within Groups	91644.430	329	278.554		
Total	129589.044	335			

Statistical analysis of % cell viability by LSD post-hoc test (multiple comparisons)

Multiple Comparisons

%viability LSD		Mean Difference (I- J)	Std. Error	Sig.	95% Confidence Interval	
(I) concentration of CCM	(J) concentration of CCM				Lower Bound	Upper Bound
0 uM	0.1 uM	-1.49313	3.40682	.661	-8.1950	5.2088
	1 uM	-6.31937	3.40682	.065	-13.0213	.3825
	10 uM	-.19042	3.40682	.955	-6.8923	6.5115
	20 uM	-4.05021	3.40682	.235	-10.7521	2.6517
	30 uM	8.56625*	3.40682	.012	1.8643	15.2682
	50 uM	27.17937*	3.40682	.000	20.4775	33.8813
0.1 uM	0 uM	1.49313	3.40682	.661	-5.2088	8.1950
	1 uM	-4.82625	3.40682	.158	-11.5282	1.8757
	10 uM	1.30271	3.40682	.702	-5.3992	8.0046
	20 uM	-2.55708	3.40682	.453	-9.2590	4.1448
	30 uM	10.05938*	3.40682	.003	3.3575	16.7613
	50 uM	28.67250*	3.40682	.000	21.9706	35.3744
1 uM	0 uM	6.31937	3.40682	.065	-.3825	13.0213
	0.1 uM	4.82625	3.40682	.158	-1.8757	11.5282
	10 uM	6.12896	3.40682	.073	-.5729	12.8309
	20 uM	2.26917	3.40682	.506	-4.4327	8.9711
	30 uM	14.88563*	3.40682	.000	8.1837	21.5875
	50 uM	33.49875*	3.40682	.000	26.7968	40.2007
10 uM	0 uM	-.19042	3.40682	.955	-6.5115	6.8923
	0.1 uM	-1.30271	3.40682	.702	-8.0046	5.3992
	1 uM	-6.12896	3.40682	.073	-12.8309	.5729
	20 uM	-3.85979	3.40682	.258	-10.5617	2.8421
	30 uM	8.75667*	3.40682	.011	2.0548	15.4586
	50 uM	27.36979*	3.40682	.000	20.6679	34.0717
20 uM	0 uM	4.05021	3.40682	.235	-2.6517	10.7521
	0.1 uM	2.55708	3.40682	.453	-4.1448	9.2590
	1 uM	-2.26917	3.40682	.506	-8.9711	4.4327
	10 uM	3.85979	3.40682	.258	-2.8421	10.5617
	30 uM	12.61646*	3.40682	.000	5.9146	19.3184
	50 uM	31.22958*	3.40682	.000	24.5277	37.9315
30 uM	0 uM	-8.56625*	3.40682	.012	-15.2682	-1.8643
	0.1 uM	-10.05938*	3.40682	.003	-16.7613	-3.3575
	1 uM	-14.88563*	3.40682	.000	-21.5875	-8.1837
	10 uM	-8.75667*	3.40682	.011	-15.4586	-2.0548
	20 uM	-12.61646*	3.40682	.000	-19.3184	-5.9146
	50 uM	18.61312*	3.40682	.000	11.9112	25.3150
50 uM	0 uM	-27.17937*	3.40682	.000	-33.8813	-20.4775
	0.1 uM	-28.67250*	3.40682	.000	-35.3744	-21.9706
	1 uM	-33.49875*	3.40682	.000	-40.2007	-26.7968
	10 uM	-27.36979*	3.40682	.000	-34.0717	-20.6679
	20 uM	-31.22958*	3.40682	.000	-37.9315	-24.5277
	30 uM	-18.61312*	3.40682	.000	-25.3150	-11.9112

*. The mean difference is significant at the 0.05 level.

Statistical analysis of TGF- β 1 gene expression by Kruskal-Wallis Test

Kruskal-Wallis Test

Ranks

concentration of CCM		N	Mean Rank
TGFb1 fold change	0 uM	3	3.00
	0.1 uM	3	8.33
	1 uM	3	8.67
	10 uM	3	9.67
	20 uM	3	10.33
	Total	15	

Test Statistics^{a,b}

	TGFb1 fold change
Chi-Square	5.103
df	4
Asymp. Sig.	.277

a. Kruskal Wallis Test

b. Grouping Variable:
concentration of CCM



Statistical analysis of TGF β R I gene expression by Kruskal-Wallis Test

Kruskal-Wallis Test

Ranks

concentration of CCM		N	Mean Rank
TGFbr1 fold change	0 uM	3	8.50
	0.1 uM	3	4.50
	1 uM	3	11.00
	10 uM	3	10.17
	20 uM	3	5.83
	Total	15	

Test Statistics^{a,b}

	TGFbr1 fold change
Chi-Square	4.735
df	4
Asymp. Sig.	.316

a. Kruskal Wallis Test

b. Grouping Variable:
concentration of CCM

Statistical analysis of TGFBR II gene expression by Kruskal-Wallis Test

Kruskal-Wallis Test

Ranks

concentration of CCM		N	Mean Rank
TGFbr2 fold change	0 uM	3	4.50
	0.1 uM	3	10.33
	1 uM	3	9.67
	10 uM	3	9.50
	20 uM	3	6.00
	Total	15	

Test Statistics^{a,b}

	TGFbr2 fold change
Chi-Square	4.089
df	4
Asymp. Sig.	.394

a. Kruskal Wallis Test

b. Grouping Variable:
concentration of CCM



Statistical analysis of VEGF gene expression by Kruskal-Wallis Test

Kruskal-Wallis Test

Ranks

concentration of CCM		N	Mean Rank
VEGF fold change	0 uM	3	8.00
	0.1 uM	3	6.50
	1 uM	3	9.50
	10 uM	3	9.00
	20 uM	3	7.00
	Total	15	

Test Statistics^{a,b}

	VEGF fold change
Chi-Square	.984
df	4
Asymp. Sig.	.912

a. Kruskal Wallis Test

b. Grouping Variable:
concentration of CCM

VITA

Miss Auspreeya Rujirachotiwat graduated with First class honors of D.D.S. (Doctor of Dental Surgery) from Faculty of Dentistry, Chulalongkorn University in 2012, and had worked at Banphue hospital in Udon Thani province for 3 years. She started her Master degree program and residency training program in Pediatric Dentistry at Graduate School, Chulalongkorn University in 2015.

